This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Asahi Kasei Pharma Corporation, Raqualia Pharma Inc.. Active years: 2021-2025.
Company Filing History:
3 out of 84 
3 out of 47 Years Active: 2021-2025
Title: Kazuki Toyoshima: Innovator in Pharmaceutical Chemistry
Introduction
Kazuki Toyoshima is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for therapeutic applications. With a total of 3 patents to his name, Toyoshima's work focuses on innovative solutions for medical challenges.
Latest Patents
Among his latest patents, Toyoshima has developed tetrahydroquinoline derivatives as P2X7 receptor antagonists. This invention relates to tetrahydroquinoline derivatives, their pharmaceutically acceptable salts, and prodrugs. The patent outlines processes for their preparation, pharmaceutical compositions containing these compounds, and their potential use in treating various disorders mediated via the P2X7 receptor.
Career Highlights
Kazuki Toyoshima has worked with notable companies in the pharmaceutical industry, including Raqualia Pharma Inc. and Asahi Kasei Pharma Corporation. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in drug development.
Collaborations
Throughout his career, Toyoshima has collaborated with esteemed colleagues such as Yoshimasa Arano and Toshihiko Sone. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Kazuki Toyoshima stands out as a key figure in pharmaceutical innovation, with a focus on developing effective treatments through his patented inventions. His contributions continue to impact the field positively.